Reference is made to the stock exchange release published by Arctic Bioscience 22 February 2022 regarding exercise of share options and corresponding issuance of new shares in Arctic Bioscience.
On 23 February 2022, the board of Arctic Bioscience, on the basis of a board authorization granted by the general meeting, resolved to increase the share capital from NOK 2,429,953.90, a share capital increase of by NOK 7,618 to NOK 2,437,571.90 by subscription of 76,180 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 9.845 per share, including a share premium of NOK 9.745.
The total amount paid as share premium is NOK 742,374.10. The total subscription amount is
NOK 749,992.10. Following the registration of this share capital increase in the
Norwegian Register of Business Enterprises, the Company’s share capital will be
NOK 2,437,571.90 divided into 24,375,719 shares, each having a nominal value of NOK 0.10.
“Minutes form Board Meeting” and “Notification of transactions by persons discharging managerial responsibilities” are attached hereto.
For further information, please contact:
CFO of Arctic Bioscience AS
Phone: +47 909 98 201
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing nutraceutical products based on herring roe oil. Herring roe oil contains lipids that are essential to maintain cell membranes, contributing to normal functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients to other companies making dietary supplements, and as finished goods under the Romega brand. The strategy is to switch sales from bulk to finished goods and focus markets are USA and China.
The company is developing HRO350 – a novel investigational drug candidate with herring roe as raw material. HRO350 is being developed for treatment of mild-to -moderate psoriasis. This is a large patient group in need of new effective medicines. Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.